KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to -$717.9 million.

  • Regeneron Pharmaceuticals' Cash from Financing Activities fell 13.23% to -$717.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 billion, marking a year-over-year decrease of 169.39%. This contributed to the annual value of -$2.2 billion for FY2024, which is 22.93% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Cash from Financing Activities of -$717.9 million as of Q3 2025, which was up 36.37% from -$1.1 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities registered a high of $385.4 million during Q3 2021, and its lowest value of -$1.1 billion during Q4 2024.
  • Its 3-year average for Cash from Financing Activities is -$629.6 million, with a median of -$614.2 million in 2023.
  • In the last 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities surged by 117.66% in 2022 and then crashed by 2,412.53% in 2025.
  • Regeneron Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at -$906.6 million in 2021, then spiked by 72.69% to -$247.6 million in 2022, then crashed by 80.17% to -$446.1 million in 2023, then slumped by 154.54% to -$1.1 billion in 2024, then declined by 13.23% to -$717.9 million in 2025.
  • Its Cash from Financing Activities was -$717.9 million in Q3 2025, compared to -$1.1 billion in Q2 2025 and -$1.1 billion in Q1 2025.